Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program

Neuropathology - Tập 35 Số 4 - Trang 354-389 - 2015
Thomas G. Beach1, Charles H. Adler2, Lucia I. Sue1, Geidy E. Serrano1, Holly A. Shill1, Douglas G. Walker1, Lih‐Fen Lue1, Alex E. Roher1, Brittany N. Dugger1, Chera L. Maarouf1, Alex C. Birdsill1, Anthony J. Intorcia1, Megan Saxon‐LaBelle1, Joel Pullen1, Alexander Scroggins1, Jessica Filon1, Sarah Scott1, Brittany Hoffman1, Angelica Garcia1, John N. Caviness2, Joseph G. Hentz2, Erika Driver‐Dunckley2, Sandra A. Jacobson1, Kathryn Davis1, Christine M. Belden1, Kathy E. Long1, Michael Malek‐Ahmadi1, Jessica Powell1, Lisa D. Gale1, Lisa R. Nicholson1, Richard J. Caselli2, Bryan K. Woodruff2, Steven Z. Rapscak3, Geoffrey L. Ahern3, Jiong Shi4, Anna Burke5, Eric M. Reiman5, Marwan N. Sabbagh1
1Banner Sun Health Research Institute, Sun City, Arizona, USA
2Mayo Clinic, Scottsdale, Arizona, USA
3University of Arizona, Tucson, Arizona, USA
4Barrow Neurological Institute, Phoenix, Arizona, USA
5Banner Alzheimer Institute, Phoenix, Arizona, USA

Tóm tắt

The Brain and Body Donation Program (BBDP) at Banner Sun Health Research Institute (http://www.brainandbodydonationprogram.org) started in 1987 with brain‐only donations and currently has banked more than 1600 brains. More than 430 whole‐body donations have been received since this service was commenced in 2005. The collective academic output of the BBDP is now described as the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND). Most BBDP subjects are enrolled as cognitively normal volunteers residing in the retirement communities of metropolitan Phoenix, Arizona. Specific recruitment efforts are also directed at subjects with Alzheimer's disease, Parkinson's disease and cancer. The median age at death is 82. Subjects receive standardized general medical, neurological, neuropsychological and movement disorders assessments during life and more than 90% receive full pathological examinations by medically licensed pathologists after death. The Program has been funded through a combination of internal, federal and state of Arizona grants as well as user fees and pharmaceutical industry collaborations. Subsets of the Program are utilized by the US National Institute on Aging Arizona Alzheimer's Disease Core Center and the US National Institute of Neurological Disorders and Stroke National Brain and Tissue Resource for Parkinson's Disease and Related Disorders. Substantial funding has also been received from the Michael J. Fox Foundation for Parkinson's Research. The Program has made rapid autopsy a priority, with a 3.0‐hour median post‐mortem interval for the entire collection. The median RNA Integrity Number (RIN) for frozen brain and body tissue is 8.9 and 7.4, respectively. More than 2500 tissue requests have been served and currently about 200 are served annually. These requests have been made by more than 400 investigators located in 32 US states and 15 countries. Tissue from the BBDP has contributed to more than 350 publications and more than 200 grant‐funded projects.

Từ khóa


Tài liệu tham khảo

Beach TG, 2013, Alzheimer's disease and the “Valley of Death”: not enough guidance from human brain tissue?, J Alzheimers Dis, 33, S219

10.1016/S0049-0172(99)80003-1

10.1006/jaut.1999.0305

10.1016/S0531-5565(02)00178-X

10.1097/00041444-200403000-00003

10.1016/0304-3940(92)90552-I

10.1111/j.1600-0447.1997.tb09924.x

10.1023/A:1007772931154

10.1016/S0306-4603(00)00064-2

10.1111/j.1532-5415.1999.tb02571.x

10.1373/clinchem.2010.150672

Nelkin D, 1998, Do the dead have interests? Policy issues for research after life, Am J Law Med, 24, 261, 10.1017/S0098858800010431

KurtzSF StrongCWGD.The 2006 revised Uniform Anatomical Gift Act – A law to save lives.Health Lawyers News2007;February:44–49.

10.1093/brain/102.2.333

10.1111/j.1471-4159.1978.tb12477.x

10.1371/journal.pone.0021405

10.1520/JFS13456J

10.1016/0003-2697(81)90083-X

10.1136/jnnp.51.3.325

10.1016/S0079-6123(08)64565-3

10.1046/j.1471-4159.2003.01747.x

10.1042/bst0160472

10.1016/0006-3223(93)90174-C

10.1038/modpathol.3880451

10.1016/S1385-299X(01)00119-2

10.1016/S0169-328X(03)00337-1

10.1016/S0169-328X(03)00208-0

10.1093/hmg/ddh065

10.1016/j.biopsych.2003.10.013

10.1097/nen.0b013e31815c196a

10.1186/1471-2164-9-91

10.1097/NEN.0b013e3181c7e32f

10.1016/0165-0270(88)90189-6

10.1016/0169-328X(93)90092-4

10.1016/0169-328X(94)00219-5

10.1016/S0165-0270(97)00115-5

10.1006/nbdi.1998.0200

10.1007/s007020050162

10.2144/04364ST03

10.1002/jnr.490160123

10.3109/00207459008985953

10.1016/0169-328X(91)90018-S

10.1073/pnas.88.5.1854

10.1111/j.1471-4159.1992.tb10057.x

10.1016/0306-4522(94)90292-5

10.1007/BF02088715

10.1016/0304-3940(95)12102-A

10.1101/gr.10.8.1219

10.1016/j.legalmed.2003.08.001

10.1016/j.neuint.2006.01.018

10.1155/2012/614212

10.1007/s10561-010-9210-8

10.1002/cncr.25405

10.1093/jnen/62.8.855

10.1097/NEN.0b013e31824b211b

10.1021/pr060160v

10.1002/pmic.200300822

10.1021/ac702422x

10.1373/clinchem.2006.070508

10.1371/journal.pone.0094839

10.3109/13547500903108423

10.2174/156720509788929318

10.1179/1743132812Y.0000000063

Maarouf CL, 2013, Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology, Biomark Insights, 8, 19, 10.4137/BMI.S11422

10.1179/016164106X98035

10.1002/mds.25555

10.1016/j.jneumeth.2010.06.017

10.1007/s00401-011-0808-0

10.1016/S0002-9440(10)64947-4

10.1007/s00401-009-0538-8

10.1016/j.mcn.2014.04.003

10.1007/s12035-010-8106-8

10.1002/jnr.20484

10.1016/0197-4580(96)00006-1

10.1002/jnr.10422

Rogers J, 2002, Elucidating molecular mechanisms of Alzheimer's disease in microglial cultures, Ernst Schering Res Found Workshop, 39, 25

10.1007/BF03402043

10.1097/00005072-199501000-00006

10.1016/S0165-0270(87)80001-8

10.3109/00313028909061071

10.1177/35.11.3309048

10.1007/s00401-008-0409-8

10.1111/j.1750-3639.1991.tb00661.x

10.1016/S0197-4580(97)00049-3

10.1007/BF00308809

10.1212/WNL.58.12.1791

10.1016/0022-510X(89)90197-4

10.1016/0304-3940(89)90479-5

10.1007/BF00687251

10.1097/00005072-199005000-00003

10.1007/BF00296114

10.1007/BF00296188

10.1007/BF00334887

10.1007/BF00308476

10.1111/j.1365-2990.1993.tb00453.x

10.1016/S1474-4422(12)70142-4

10.1097/NEN.0000000000000028

10.1097/WAD.0b013e31821300bc

10.1179/016164104225017668

10.1007/s004010000283

10.1016/j.parkreldis.2011.02.017

10.1007/s00401-013-1110-0

10.1212/WNL.41.4.479

10.1097/00005072-199710000-00002

10.1007/s00401-011-0910-3

10.1212/01.wnl.0000187889.17253.b1

10.1016/S0166-2236(98)01362-9

10.1111/j.1699-0463.1988.tb00954.x

10.1007/s00401-007-0313-7

10.1007/s00401-006-0136-y

10.1161/01.ATV.0000095973.42032.44

Roher AE, 2013, Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations, Am J Neurodegener Dis, 2, 187

10.1016/j.neuint.2012.12.001

10.1016/j.parkreldis.2014.02.012

10.1007/s00401-009-0620-2

10.1021/bi026173d

10.1212/WNL.0b013e31828c2f52

10.1097/NEN.0b013e31825018f7

10.1161/01.STR.0000110791.51378.4E

10.1161/STROKEAHA.110.595082

10.1212/WNL.43.2.250

10.1007/s00401-011-0845-8

10.1001/archneur.56.1.33

10.1016/S1474-4422(09)70238-8

10.1007/s00401-004-0950-z

10.1016/j.jalz.2011.10.007

10.1097/NEN.0000000000000046

10.1097/WAD.0b013e318199d833

Jellinger KA, 2014, Challenges of multimorbidity of the aging brain: a critical update, J Neural Transm

10.1016/1043-4682(95)90011-X

10.1016/S0022-2275(20)43176-1

10.1111/j.1750-3639.2003.tb00027.x

10.1136/jnnp.69.5.574

10.1097/WAD.0000000000000046

10.1016/j.neurol.2013.07.014

10.1186/alzrt130

10.1016/0304-3940(82)90334-2

10.1046/j.1471-4159.1995.64010235.x

10.1007/BF01251916

10.1016/j.brainres.2006.09.025

10.1111/j.1471-4159.1990.tb04948.x

10.1007/s10561-008-9067-2

10.1016/j.molbrainres.2005.04.017

10.1520/JFS13445J

10.1097/PDM.0b013e3181857e92

10.1016/j.amjcard.2005.12.031

10.1179/016164106X130515

10.1212/01.wnl.0000172914.08967.dc

10.1136/bmj.322.7300.1447

10.1016/S0197-4580(00)00096-8

10.1016/S0140-6736(96)90608-X

10.1371/journal.pone.0012538

10.1179/016164106X130498

10.1212/01.WNL.0000161870.78572.A5

10.1179/016164106X130407

10.1177/153331750201700210

10.1111/j.1532-5415.1988.tb01804.x

10.1161/01.STR.30.3.613

10.2147/VHRM.S34874

10.1016/j.jalz.2010.09.002

10.1161/01.STR.0000143317.70478.b3

10.1212/WNL.65.6.974

10.1161/01.ATV.0000095973.42032.44

10.1016/j.jalz.2010.08.228

10.1186/1471-2318-11-3

10.7863/jum.2009.28.11.1493

10.1016/0167-4943(94)00600-C

10.1093/oxfordjournals.aje.a115542

10.1016/0021-9150(91)90240-4

10.3143/geriatrics.28.188

10.1161/01.ATV.10.4.535

10.1016/0021-9150(88)90075-5

10.1212/01.WNL.0000150886.50187.30

10.1161/01.STR.26.5.743

10.1046/j.1468-1331.1999.640415.x

10.1111/j.1532-5415.1998.tb04537.x

10.1111/j.1532-5415.1996.tb00912.x

10.1007/s00415-004-0316-4

10.1111/j.1532-5415.1996.tb01362.x

10.2174/1567205010666131120110930

10.1007/s00401-010-0664-3

10.1097/NEN.0b013e318258381b

10.1097/NEN.0b013e3182965886

10.1097/NEN.0b013e3182801cde

10.1007/s00401-012-1040-2

10.1016/j.neulet.2014.04.027

10.1212/WNL.0000000000000641

Beach TG, 2013, Alzheimer's disease and the “valley of death”: not enough guidance from human brain tissue?, J Alzheimers Dis, 33, S219, 10.3233/JAD-2012-129020

10.1097/NEN.0b013e3182805c72

10.1212/WNL.0000000000000204

10.1097/CCO.0b013e32834161b8

10.1093/jncimonographs/lgr007

10.1093/jncimonographs/lgr008

10.1245/s10434-010-0959-6

10.1371/journal.pone.0041371

10.1371/journal.pone.0045614

10.1088/1478-3975/9/6/065004

10.1158/0008-5472.CAN-09-4008

10.1038/ng.859

10.1016/j.neurobiolaging.2012.02.005

10.1001/archneurol.2012.2052

10.1371/journal.pone.0058618

10.1001/jama.2013.2973

10.1093/hmg/dds161

10.1016/S1474-4422(07)70221-1

10.1001/archneurol.2011.53

10.1038/ng.536

10.1038/ng.801

10.1038/ng.2802

Blitterswijk M, 2014, Ataxin‐2 as potential disease modifier in C9ORF72 expansion carriers, Neurobiol Aging, 35, 2421

10.1007/s00401-013-1240-4

10.1212/WNL.0b013e3182a8250c

10.1016/S1474-4422(13)70210-2

10.1111/ahg.12000

10.1158/0008-5472.CAN-10-2585

10.1371/journal.pone.0054096

10.1038/ng.2466

10.1371/journal.pgen.1002794

10.1371/journal.pone.0046199

10.1371/journal.pgen.1002707

10.1126/scitranslmed.3001059

10.1016/j.neurobiolaging.2014.03.031

10.1189/jlb.0705377

10.1002/mds.22184

10.1073/pnas.0709259105

10.1152/physiolgenomics.00242.2007

10.1152/physiolgenomics.00208.2006

10.1016/j.neurobiolaging.2008.05.013

10.1016/j.neurobiolaging.2006.08.014

10.1016/j.yexcr.2006.10.028

10.1016/j.neurobiolaging.2005.08.013

10.1016/j.neuron.2007.05.022

10.1016/j.mito.2006.07.002

10.1159/000110789

10.1016/j.ajhg.2009.03.011

10.1212/WNL.0b013e31820a0e3b

10.1261/rna.036863.112

10.1016/j.neurobiolaging.2008.12.005

10.1016/j.neurobiolaging.2013.02.021

10.1038/srep05797

10.3233/JAD-2011-111340

Dugger BN, 2012, Presence of striatal amyloid plaques in Parkinson's disease dementia predicts concomitant Alzheimer's disease: usefulness for amyloid imaging, J Parkinsons Dis, 2, 57, 10.3233/JPD-2012-11073

Serrano GE, 2014, Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43‐positive inclusions, J Alzheimers Dis, 42, 813, 10.3233/JAD-140162

10.1093/brain/awm191

10.1111/j.1471-4159.2009.05996.x

10.1111/j.1471-4159.2008.05245.x

10.2174/187152709787847315

10.1186/1750-1326-5-39

10.2353/ajpath.2006.060269

10.1371/journal.pone.0059735

10.3233/JAD-2011-101809

10.1016/j.mvr.2007.10.004

10.1016/S0197-4580(01)00311-6

10.1002/glia.1072

10.1016/S0197-0186(01)00040-7

10.1016/S0197-4580(01)00306-2

10.1046/j.1471-4159.2000.0751447.x

10.1093/hmg/ddt208

10.1016/j.neulet.2011.07.048

10.1016/j.jneumeth.2014.06.014

10.1111/j.1750-3639.2012.00597.x

10.1111/j.1750-3639.2012.00585.x

10.1016/j.expneurol.2012.11.020

10.1371/journal.pone.0077711

10.1093/jnen/63.4.329

10.1007/s00401-007-0250-5

10.1016/S0006-8993(02)03396-6

10.1016/S1353-8020(00)00060-2

10.1016/S1353-8020(02)00012-3

Beach TG, 1998, Neurofibrillary tangles are constant in aging human nucleus basalis, Alzheimers Rep, 1, 375

10.1093/jnen/59.4.308

10.1007/s00401-011-0831-1

10.1016/j.expneurol.2008.09.003

10.1016/S0197-4580(00)00124-X

10.1016/j.neurobiolaging.2005.09.043

10.1016/S0169-328X(00)00149-2

10.1016/0014-4886(90)90054-V

10.1159/000051265

10.1016/S0197-4580(97)00042-0

Webster S, 1997, Charge‐based binding of complement component C1q to the Alzheimer amyloid beta‐peptide, Am J Pathol, 150, 1531

10.1046/j.1471-4159.1997.69010388.x

10.1002/(SICI)1097-4547(19961001)46:1<58::AID-JNR8>3.0.CO;2-E

10.1006/bbrc.1995.2852

10.1097/00005072-199911000-00003

10.1097/00005072-199655100-00008

10.1006/exnr.2001.7732

10.2174/1568007054038210

10.1007/s00401-007-0250-5

10.1267/ahc.10022

Morimoto K, 2011, Expression profiles of cytokines in the brains of Alzheimer's disease (AD) patients compared to the brains of non‐demented patients with and without increasing AD pathology, J Alzheimers Dis, 25, 59, 10.3233/JAD-2011-101815

Tharp WG, 2012, Measurement of altered AbetaPP isoform expression in frontal cortex of patients with Alzheimer's disease by absolute quantification real‐time PCR, J Alzheimers Dis, 29, 449, 10.3233/JAD-2011-111337

10.1016/S0304-3940(03)00567-6

10.1016/j.neulet.2010.02.016

10.1523/JNEUROSCI.20-10-03606.2000

10.1006/bbrc.1997.7083

10.1016/S0925-4439(98)00014-3

10.1006/bbrc.2000.2222

10.1074/jbc.M007859200

10.1006/bbrc.1998.9652

10.1016/S0002-9440(10)65184-X

10.1016/S0925-4439(00)00030-2

10.2119/2007-00094.VanVickle

10.1016/j.bbadis.2011.07.004

10.1006/bbrc.1999.0552

10.1186/1750-1326-3-20

10.1371/journal.pone.0027291

10.1074/jbc.M311380200

10.2174/1567205011310030010

10.1016/j.neurobiolaging.2014.03.022

10.1212/WNL.0000000000000417

10.1016/j.sleep.2012.10.015

10.1016/j.parkreldis.2011.03.007

10.1002/mds.23509

10.1002/mds.25954

10.1016/S1353-8020(11)70042-6

10.1002/mds.24004

10.1002/mds.22479

10.1016/j.sleep.2013.08.781

10.1002/mds.25845

10.1212/01.wnl.0000310425.76205.02

10.1016/j.clinph.2011.03.033

Caviness JN, 2006, Quantitative electroencephalography can distinguish between Parkinson's disease patient groups classified according to clinical cognitive dysfunction and neuropsychometric performance, Neurology, 66, A210

10.1002/mds.10177

10.1016/S1353-8020(01)00007-4

10.1002/mds.23697

10.1002/mds.10525

10.1212/WNL.60.3.523

10.1016/j.parkreldis.2007.01.003

10.1002/mds.20743

10.1212/WNL.0b013e318224af8d

10.1159/000108340

10.2174/156720510791162340

10.1016/j.parkreldis.2005.02.004

10.1016/S1353-8020(09)70787-4

10.1002/mds.21453

10.1001/archneur.63.12.1771

10.1002/mds.22971

Caviness JN, 2002, Myoclonus in Lewy body disorders, Adv Neurol, 89, 23

10.1016/j.parkreldis.2012.06.008

10.1016/j.forsciint.2012.03.010

10.1097/NEN.0000000000000114

10.1093/brain/awn016

10.1002/ana.22100

10.1007/s00401-012-1051-z

10.1212/01.wnl.0000271090.28148.24